Grant of Share Options - replacement
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your RENX notes
The following amendment has been made to the ' Grant of Share Options' announcement released on 23 November 2023 at 07:00 under RNS No 3917U.
The sentence "All the Share Options granted one twelfth of the Share Options vest 3 months from the date of grant with one twelfth vesting quarterly after that, subject to the individuals remaining employed by the Company as Non-Executive Directors" has been removed and replaced with "The share option grant would vest 100% in 12 months from date of grant".
All other details remain unchanged.
The full amended text is shown below.
Renalytix plc
("Renalytix" or the "Company")
Grant of Share Options
LONDON and SALT LAKE CITY - November 23, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that the Board have granted options over a total of 380,000 ordinary shares of 0.25 pence each in the capital of the Company (the "Share Options") to the following individuals:
| Name | Position | Options granted |
|---|---|---|
| Christopher Mills | Non-Executive Chairman | 95,000 |
| Daniel Levangie | Non-Executive Director | 95,000 |
| Chirag Parikh | Non-Executive Director | 95,000 |
| Catherine Coste | Non-Executive Director | 95,000 |
The Share Options, which have been issued in line with the Company's existing share option plan, have an exercise price of £0.245 per ordinary share, being the closing price of the shares on the 17 November 2023.
The share option grant would vest 100% in 12 months from date of grant.
The issue of the Share Options are deemed to be related party transactions pursuant to AIM Rule 13 of the AIM Rules for Companies. The Company's directors (excluding those who are being awarded the Share Options) consider, having consulted with the Nominated Adviser, Stifel Nicolaus Europe Limited, that the terms of the related party transactions are fair and reasonable insofar as the shareholders of the Company are concerned.
| a) | Name | Christopher Mills |
| 2 | Reason for the notification | |
| a) | Position/status | Non-Executive Chairman |
| b) | Initial notification /Amendment | Initial notification |
| a) | Name | Renalytix plc |
| b) | LEI | 213800NTOH3FK3WER551 |
| a) | Description of the financial instrument, type of instrument | Options over ordinary shares of 0.25 pence each in the Company |
| Identification code | GB00BYWL4Y04 | |
| b) | Nature of the transaction | Grant of options over shares |
| c) | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| £0.245 | 95,000 | |
| d) | Aggregated information | |
| - Aggregated volume | 95,000 | |
| - Price | £23,275 | |
| e) | Date of the transaction | 21 November 2023 |
| f) | Place of the transaction | Outside of trading venue - off market |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Dan Levangie |
| 2 | Reason for the notification | |
| a) | Position/status | Non-Executive Director |
| b) | Initial notification /Amendment | Initial notification |
| a) | Name | Renalytix plc |
| b) | LEI | 213800NTOH3FK3WER551 |
| a) | Description of the financial instrument, type of instrument | Options over ordinary shares of 0.25 pence each in the Company |
| Identification code | GB00BYWL4Y04 | |
| b) | Nature of the transaction | Grant of options over shares |
| c) | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| £0.245 | 95,000 | |
| d) | Aggregated information | |
| - Aggregated volume | 95,000 | |
| - Price | £23,275 | |
| e) | Date of the transaction | 21 November 2023 |
| f) | Place of the transaction | Outside of trading venue - off market |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Chirag Parikh |
| 2 | Reason for the notification | |
| a) | Position/status | Non-Executive Director |
| b) | Initial notification /Amendment | Initial notification |
| a) | Name | Renalytix plc |
| b) | LEI | 213800NTOH3FK3WER551 |
| a) | Description of the financial instrument, type of instrument | Options over ordinary shares of 0.25 pence each in the Company |
| Identification code | GB00BYWL4Y04 | |
| b) | Nature of the transaction | Grant of options over shares |
| c) | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| £0.245 | 95,000 | |
| d) | Aggregated information | |
| - Aggregated volume | 95,000 | |
| - Price | £23,275 | |
| e) | Date of the transaction | 21 November 2023 |
| f) | Place of the transaction | Outside of trading venue - off market |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Catherine Coste |
| 2 | Reason for the notification | |
| a) | Position/status | Non-Executive Director |
| b) | Initial notification /Amendment | Initial notification |
| a) | Name | Renalytix plc |
| b) | LEI | 213800NTOH3FK3WER551 |
| a) | Description of the financial instrument, type of instrument | Options over ordinary shares of 0.25 pence each in the Company |
| Identification code | GB00BYWL4Y04 | |
| b) | Nature of the transaction | Grant of options over shares |
| c) | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| £0.245 | 95,000 | |
| d) | Aggregated information | |
| - Aggregated volume | 95,000 | |
| - Price | £23,275 | |
| e) | Date of the transaction | 21 November 2023 |
| f) | Place of the transaction | Outside of trading venue - off market |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.